Analytical Data
-
Gene name
HLA-A*02:01&B2M&PRAME(SLLQHLIGL) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & PRAME (SLLQHLIGL)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&SLLQHLIGL
-
Molecular Weight
58-61 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01/B2M/PRAME(SLLQHLIGL) monomer represents a critical focus in immunological research, particularly in the context of cancer immunotherapy. HLA-A*02:01 is a highly prevalent human leukocyte antigen class I molecule, pivotal for presenting peptide antigens to CD8+ cytotoxic T lymphocytes. PRAME (Preferentially Expressed Antigen in Melanoma) is an oncofetal antigen typically overexpressed in various cancers, making it a prime target for T-cell-mediated immune responses. The specific epitope SLLQHLIGL is derived from PRAME and has been shown to elicit strong T-cell responses in HLA-A*02:01 positive individuals. Engineering a recombinant protein comprising HLA-A*02:01, beta-2-microglobulin (B2M), and the PRAME epitope allows for detailed analysis of T-cell activation and the development of novel therapeutic strategies. Studying this monomer aids in elucidating the molecular interactions involved in antigen presentation, enhancing our understanding of T-cell recognition and facilitating the design of cancer vaccines and adoptive T-cell therapies. Furthermore, this research is essential for improving patient outcomes in immunotherapy by identifying effective antigenic targets that can stimulate robust anti-tumor responses while minimizing immune evasion mechanisms employed by tumors.
